Vertex announces positive results from phase 2 study of vx-147 in apol1-mediated focal segmental glomerulosclerosis

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that, in a phase 2 proof-of-concept (poc) study in patients with apol1-mediated focal segmental glomerulosclerosis (fsgs), vx-147 on top of standard of care achieved a statistically significant, substantial and clinically meaningful mean reduction of 47.6% in the urine protein to creatinine ratio (upcr) at week 13 compared to baseline. vx-147 was well tolerated. these results provide the first clinical e
VRTX Ratings Summary
VRTX Quant Ranking